UBS O'Connor Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$184M |
| 2 |
First Horizon
FHN
|
+$107M |
| 3 |
SGFY
Signify Health, Inc.
SGFY
|
+$54.9M |
| 4 |
VMW
VMware, Inc
VMW
|
+$34.9M |
| 5 |
ONEM
1Life Healthcare
ONEM
|
+$29.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$572M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$456M |
| 3 |
Rogers Corp
ROG
|
+$432M |
| 4 |
AVLR
Avalara, Inc.
AVLR
|
+$373M |
| 5 |
SWCH
Switch, Inc. Class A Common Stock
SWCH
|
+$271M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.54% |
| 2 | Healthcare | 36.97% |
| 3 | Financials | 14.43% |
| 4 | Communication Services | 3.06% |
| 5 | Energy | 0% |
Similar funds
UBS O'Connor's Q4 2022 Portfolio in Review
As of Q4 2022, UBS O'Connor held 929 positions worth $1.52B, down 83% from $8.8B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
UBS O'Connor withdrew a net $6.76B in Q4 2022, closing 920 positions and reducing 3 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.
By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.
Against the trend, UBS O'Connor added an estimated $184M to Horizon Therapeutics Public Limited Company Ordinary Shares.
- UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
- UBS O'Connor's biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $45.3M.
- UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
- UBS O'Connor's ten largest holdings make up 100% of its $1.52B portfolio in Q4 2022.
- UBS O'Connor opened 0 new positions and closed 920 in Q4 2022.
- UBS O'Connor's portfolio value fell 83% quarter-over-quarter to $1.52B.
Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.